Podcasts about transplantation

This week we speak with Dr. John Brown who is the Harris B. Schumacker Professor Emeritus of Surgery at the University of Indiana. A congenital heart surgeon for over 45 years, Dr. Brown has performed more than 15,000 pediatric heart operations at Riley Hospital for Children and another 5000 heart operations in adults at IU and Methodist Hospitals. He performed the first pediatric heart transplant in Indiana and developed the first clinical use of the bovine jugular vein and valve for a pulmonary valve replacment in children. He also performed the only known twin to twin newborn heart transplant in the world. He has done and seen it all and has a unique perspective. How did he achieve so much and still have a succesful 56 year marriage to his wife Carol Ann? What is Dr. Brown most proud of in a career that is as prolific as his? What advice would he have have for the next generation? Prepare to be inspired by this master surgeon and friend and colleague of many in our field.

Last time we talked about kidney xenotransplantation, we were joined by Towana Loony and Tim Andrews, who shared their personal experiences with receiving a xenotransplant. Today, two doctors who helped propel xenotransplantation forward, Dr. Vineeta Kumar and Dr. Leonardo Riella, are here to explain the science and what comes next. This episode is supported by eGenesis and United Therapeutics In this episode we heard from:  Vineeta Kumar is the lead nephrologist for UAB's Living Kidney Donor and Incompatible Kidney Transplant programs. She is an expert in kidney transplantation, living kidney donation, incompatible kidney transplant, kidney paired donation and cardiovascular outcomes after kidney transplantation. Kumar also engages in research in the prevention, treatment and prognosis of antibody mediated rejection. She has been named a "Top Doctor" by U.S. News & World Report each year since 2012. She has been lead facilitator of the UAB Schwartz Rounds since 2009, a program that brings together nurses, physicians, social workers, and other providers to discuss delivery of compassionate care. She was awarded the Brewer-Heslin Endowed Award for Professionalism in Medicine for the highly skilled and compassionate medical care she provides to her patients. Kumar was recently named "Best Educator" by the 2018, 2019 and 2020 UAB Medical School classes. She has previously served on the Education Committee for the American Society of Transplantation. Leonardo V. Riella, M.D., Ph.D. is the Harold and Ellen Danser Endowed Chair in Transplant Surgery at Harvard Medical School and the Medical Director of Kidney Transplantation at Massachusetts General Hospital. His research focuses on mechanisms of immune regulation and the development of novel therapies to promote transplant tolerance. In addressing kidney disease recurrence post-transplantation, he founded and leads the TANGO Consortium, the largest global effort dedicated to studying glomerular disease recurrence. In March 2024, Dr. Riella led the world's first successful kidney xenotransplant from a gene-edited pig into a living human. He now leads the first FDA-approved pilot study in kidney xenotransplantation and is conducting high-dimensional immune profiling studies to characterize the human xeno-immune response and guide immunosuppressive strategies. Find out more about Dr. Riella's research here.     Additional Resources Xenotransplantation Information   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Mary Roach explores the future of 3D-printed organs, explaining how researchers use specialized ink and support gels to recreate complex structures like heart muscles for transplantation. 2

This study of 801 multiple myeloma patients found that atrial fibrillation occurred in 5.5% within 90 days after autologous stem cell transplantation—nearly double previously reported rates—indicating disease‑specific risks. AF strongly predicted mortality from non‑relapse causes and may serve as a marker of physiological vulnerability, emphasizing the value of expanded pre‑transplant cardiac assessment and monitoring.

Was ist Schönheit?; Niedrigwasser in der Ostsee; Wie Social Media Jugendliche in den Bann zieht; Alternative Soziale Medien; Neue Erdölfördergebiete in Brasilien; Maschinenperfusion - Neue Hoffnung in der Organspende; Moderation: Marija Bakker. Von WDR 5.

At the 2026 Tandem Meetings, CancerNetwork® spoke with a variety of experts who presented on key developments and advancements across hematologic oncology. As part of different oral presentations and poster sessions, researchers and clinicians shared updated findings that may influence the management of myelodysplastic syndromes (MDS), leukemia, lymphoma, and other blood cancer types.First, Fernando Duarte, head of the Bone Marrow Transplant Service at Walter Cantídio University Hospital (HUWC), hematologist and professor at the Federal University of Ceará, and president of the Brazilian Society of Cell Therapy and Bone Marrow Transplant, highlighted his presentation analyzing trends associated with allogenic hematopoietic cell transplantation (allo-HCT) among patients with MDS or myeloproliferative neoplasms (MPN) and other types of MDS. Data from the Brazillian SBTMO and CIBMTR registry revealed that patients receiving allo-HCT for MDS/MPN were typically older with worse performance statuses. Additionally, MDS/MPN independently predicted worse overall survival (OS) and relapse-free survival outcomes.Next, Alfonso Molina, MD, MPH, a third-year Hematology and Medical Oncology fellow at Stanford University, detailed results from a phase 1 trial (NCT05507827) assessing Orca-T, an investigational allogeneic T-cell immunotherapy, among those with high-risk B-cell acute lymphoblastic leukemia (B-ALL). Treatment with Orca-T yielded disease-free survival and OS in all (100%) 18 evaluable patients after a median follow-up of 14 months (range, 3-35), which occurred without graft failure, significant graft-versus-host-disease, or severe CAR-mediated toxicity.Finally, Irtiza N. Sheikh, DO, an assistant professor in the Department of Pediatrics - Patient Care, Stem Cell Transplantation and Cellular Therapy Section of the Division of Pediatrics at The University of Texas MD Anderson Cancer Center, discussed his presentation exploring differences in outcomes with lisocabtagene maraleucel (Breyanzi; liso-cel) across various treatment settings and patient populations with large B-cell lymphoma. Data demonstrated that among patients younger than 50 years old, liso-cel produced enduring responses across real-world and clinical trial settings, which were comparable to outcomes in overall populations. References Duarte FB, Garcia YDO, Hamerschlak N, et al. Comparative outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and other myelodysplastic syndromes: Brazilian Sbtmo/CIBMTR registry analysis. Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Presentation 63. Molina A, Shiraz A, Kanegai A, et al. Mature outcomes from the phase I trial of Orca-T and allogeneic CD19/CD22 CAR-T cells for adults with high-risk B-ALL. Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Presentation 31. Sheikh IN, Patel K, Perales MA, et al. Clinical outcomes of lisocabtagene maraleucel (liso-cel) in YOUNGER PATIENTS (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Poster 210.

A heartfelt memoir about the search for religion and identity “I'm not Jewish.” For years, that's what David Weill told anyone who asked about his religious background. Yes, his father was a Jew who had left Nazi Germany as a boy. But his mother was a Southern Baptist. Growing up in New Orleans, religion wasn't something his family discussed, let alone practiced. As an adult, he developed a fervent zeal and profound devotion to his work as a specialist in organ transplants. Transplantation was all he needed to define and fulfill him—until a crisis shook him to the core. In 2015, after the simultaneous unraveling of his carefully crafted career and the death of his father, Weill began to doubt everything, including his purpose in life. While grappling with emotional pain and sinking deeper into despair, he began to suffer perplexing physical symptoms. In his moment of crisis, he was seized by a strong desire to practice a formal religion. But for Weill, the real question was, Which religion? Eventually, he chose Catholicism and was baptized at age fifty. He found solace in heart-to-heart talks with a priest and his daughters' happiness at having the whole family at church together. Everything was fine—until 2020, when he learned that his mother had converted to Judaism right before marrying his father. He was born a Jew. And in the eyes of the Jewish faith, he would always be Jewish. That realization sparked his second quest. Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

Invité, fonction, était l'invité de François Sorel dans Tech & Co, la quotidienne, ce jeudi 24 septembre. Il/Elle [est revenu(e) / a abordé / s'est penché(e) sur] [SUJET] sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

In this episode of JHLT: The Podcast, the Digital Media Editors host a discussion on a new consensus statement from ISHLT on Short Telomere Syndrome (STS) and Lung Transplantation. The document was first published last month. They're joined by document leads Andrew Courtwright, MD, PhD, of the University of Pennsylvania in Philadelphia; Dr. John Mackintosh of Prince Charles Hospital in Brisbane; and John McDyer, MD, of the University of Pittsburgh Medical Center in Pittsburgh. The conversation includes discussion of: Recommendations for assessing patients for STS Which patients we should screen How the diagnosis influences transplant decision making and risk assessment How STS impacts immunosuppression Extrapulmonary comorbidities Future areas for research ISHLT Standards, Guidelines, and Consensus Statements are open to all at ISHLT.org. For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Return later this month for a conversation on barriers and opportunities in utilizing DCD hearts in transplantation. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Juan Pablo Huidobro to discuss the key articles of the February issue of the American Journal of Transplantation. Juan Pablo Huidobro is an Assistant Professor in Nephrology at Pontifical Catholic University of Chile [02:52] Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post–C5 inhibitor era [13:22] Erythropoietin prolongs graft survival in mice by counteracting trained immunity [22:06] A new principle to attenuate ischemia reperfusion injury in kidney transplantation [33:14] Sustained allogeneic kidney graft operational tolerance despite discontinued conventional immunosuppression after CD19-CAR-T-cell therapy for relapsed/refractory post-transplantation lymphoproliferative disorder [40:15] Bloodstream Infection Subtypes and Characteristics Comparing Solid Organ Transplant and Non-Transplant Populations

Andrew Jacques, Giuliano Testa, Massimo Mangiola, Liza Johannesson. Uterus Transplantation—Current Evaluation, Monitoring, and Emerging Diagnostics. Clinical Chemistry, Volume 72, Issue 1, January 2026, Pages 18–26. https://doi.org/10.1093/clinchem/hvaf143

Dr. Michael Cooper, Chief of Transplantation at the Medical College of Wisconsin and Chair of the Board of Directors for Donate Life America, shares his perspective on recent media coverage, its impact on the organ donor registry, and what the media is missing about organ transplantation.

Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: Jared Ortaliza, “ACA Signups are Down, But Still an Incomplete Picture,” January 12, 2026, https://www.kff.org/quick-take/aca-signups-are-down-but-still-an-incomplete-picture/, KFF. Sam Gringlas, “House votes to renew ACA subsidies, as Senate Republicans rebuke Trump on Venezuela,” January 8, 2026, https://www.npr.org/2026/01/08/nx-s1-5662625/house-vote-affordable-care-act-subsidies, National Public Radio. America's Health Rankings, “2025 Annual Report,” 2025, https://assets.americashealthrankings.org/ahr_2025annual_comprehensivereport_final-web.pdf.  Elizabeth Gregerson, “Northwestern takes on its biggest rival in transplants: Time,” January 9, 2026, https://www.beckershospitalreview.com/quality/patient-safety-outcomes/northwestern-takes-on-its-biggest-rival-in-transplants-time/, Becker's Hospital Review. Mackenzie Bean, “Nation's 1st double lung-liver transplant performed at Northwestern,” March 28, 2024, https://www.beckershospitalreview.com/quality/patient-safety-outcomes/nations-1st-double-lung-liver-transplant-performed-at-northwestern/, Becker's Hospital Review. American Lunch Association, “Lung Transplant,” December 10, 2025, https://www.lung.org/lung-health-diseases/lung-procedures-and-tests/lung-transplant. Tanmay S. Panchabhai et al., “Historical perspectives of lung transplantation: connecting the dots,” July 31, 2018, https://jtd.amegroups.org/article/view/22674/html, Journal of Thoracic Disease. Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com.

Schwerste Verbrennungen galten früher als kaum überlebbar. Heute retten hochspezialisierte Medizin, innovative Hauttransplantationen und jahrelange Nachsorge viele Leben. «Puls» zeigt, warum Hoffnung auf gute Lebensqualität berechtigt ist, und begleitet Menschen, die zurück ins Leben gefunden haben. Hochspezialisierte Medizin – Besuch der Brandstation am Unispital Zürich Schwerste Verbrennungen galten früher als kaum überlebbar. Heute retten hochspezialisierte Medizin, innovative Hauttransplantationen und jahrelange Nachsorge viele Leben. «Puls» besucht die spezialisierte Intensivstation für Brandverletzte am Unispital Zürich. Dort werden mehrere Opfer der Katastrophe von Crans-Montana VS behandelt. Im Gespräch mit dem chirurgischen Leiter Bong‑Sung Kim wird deutlich, wie komplex die medizinische und emotionale Arbeit ist. Zurück ins Leben nach schweren Verbrennungen Zehn Jahre nach einem schweren Unfall spricht Luca Menegazzo mit «Puls»-Host Daniela Lager über seinen Weg zurück ins Leben. Als junger Mann erlitt er grossflächige Verbrennungen und verbrachte Wochen auf der Intensivstation. Ein starker Wille, Sport und sehr viel Unterstützung halfen ihm, neue Perspektiven zu finden. Heute steht Luca erneut in der Öffentlichkeit – um anderen Betroffenen Mut zu machen und zu zeigen: Das Leben geht weiter, auch wenn es ein harter Weg ist. Spenderhaut aus den Niederlanden – 12 Quadratmeter wurden geliefert Nach der Brandkatastrophe von Crans-Montana VS kommt lebenswichtige Hilfe aus den Niederlanden. In der Nähe von Amsterdam lagert eine der grössten Gewebebanken Europas Spenderhaut von Verstorbenen. Diese wird als temporäre Abdeckung auf offene Brandwunden transplantiert und schützt vor Infektionen sowie Flüssigkeitsverlust. Die Spenderhaut verschafft den Ärzteteams wertvolle Zeit – bis im Labor genügend eigene Haut gezüchtet werden kann und eine definitive Transplantation möglich ist. Neue Haut – Neue Perspektiven für Brandopfer Grossflächige Brandverletzungen stellen die Medizin vor enorme Herausforderungen. In Schlieren wird an einer neuen künstlichen Haut geforscht. Sie ersetzt nicht nur die Oberhaut wie bei bisherigen Verfahren, sondern zwei Hautschichten – mit dem Ziel, die Elastizität zu verbessern und Narben zu reduzieren. Bereits jetzt kommt diese im Rahmen von klinischen Studien zum Einsatz. Brandopfer David Heimer: «Meine Behandlungen sind ein Vollzeitjob» David Heimer überlebte erst vor zweieinhalb Jahren einen Fallschirmunfall mit einer Hochspannungsleitung. Rund siebzig Prozent seiner Haut wurden verbrannt, Finger amputiert, die Nase zerstört. Was braucht es alles, damit der Weg zurück ins Leben gelingt? Dank intensiver Rehabilitation und grossem mentalem Einsatz kämpft er sich zurück in ein selbstbestimmtes Leben.

Man müsste mal…eine Selbsthilfegruppe für organtransplantierte Menschen und solche, die auf ein Organ warten, gründen! Holger Niehs (60) hat das Warten hinter sich. Er weiß nicht, ob sein Herz aus Spanien oder Kroatien kommt. Er weiß auch nicht, wer der Spender oder die Spenderin war. „Das ist nicht ohne weiteres möglich und vielleicht ist es auch gut so“, meint Holger Niehs. „Wir konnten den Angehörigen der Spender anonym einen Brief schreiben und uns bedanken. Das habe ich gemacht. Der Brief kam ungeöffnet zurück:“ Holger Niehs gehört zu den Organisatoren der Selbsthilfegruppe „Zweite Chance durch Transplantation“ in Schwerin. Die Gruppe ist offen für Menschen, die auf ein Organ warten bzw. schon transplantiert sind. Auch die Angehörigen sind herzlich eingeladen. Mit der Transplantation ist in der Regel nicht alles gut und vorbei. Nimmt mein Körper das fremde Organ dauerhaft an? Komme ich mit den Medikamenten klar, die ich vielleicht über eine sehr lange Zeit nehmen muss? Kann ich eigentlich wieder arbeiten gehen? – Viele Fragen und oft keine eindeutige und klare Antwort. „Der Erfahrungsaustausch in der Gruppe ist sehr interessant und spannend“, sagt Niehs, „Das gilt auch für Betroffene, deren Transplantation schon länger her ist.“ Mehr als 8.500 Menschen stehen aktuell auf der Warteliste für eine Transplantation. Die meisten Patientinnen und Patienten warten auf eine Nierentransplantation. „2024 warteten 6.397 Menschen auf eine Spenderniere. 2024 wurden etwa 4.700 Personen neu auf die Warteliste aufgenommen. 679 Personen auf der Warteliste sind 2024 verstorben“, heißt es auf der Webseite www.organspende-info.de. Wer erfahren möchte, wie es Holger Niehs heute geht, wie sein Weg zum neuen Herzen, zur zweiten Chance verlaufen ist und welche Rolle die Selbsthilfegruppe “Zweite Chance durch Transplantation“ in seinem Leben spielt, erfährt dies in der neuen Folge vom Podcast „Man müsste mal …“ mit Andreas Lußky und Claus Oellerking. Diese Folge haben wir am 3. Oktober 2025 aufgenommen. Die angesprochenen Infos zur Patienten- / Vorsorgevollmacht findet Ihr zum Beispiel hier und hier. Webseite https://manmuesstemal.jimdofree.com/ Facebook https://www.facebook.com/manmuesstemal/ Podcast https://www.podcast.de/podcast/822137/ Spotify https://open.spotify.com/show/3G2Sici6xfKtmX4h5GJC6W iTunes https://podcasts.apple.com/de/podcast/man-m%C3%BCsste-mal/id1518142952 Instagram https://www.instagram.com/mmm.manmuesstemal/?hl=de Wir sind eine Arbeitsgruppe des Vereins Miteinander - Ma‘an e.V. Wir werden unterstützt von der Online-Zeitung „Schwerin-Lokal“. Wir werden unterstützt durch die Stiftung für Ehrenamt und bürgerschaftliches Engagement M-V Kontakt zur Selbsthilfegruppe „Zweite Chance durch Transplantation“ über KISS – Schwerin Tel.:03 85 - 39 24 333 Mail:info@kiss-sn.de

In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD(The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial Sloan Kettering Cancer Center; ID SIG Chair), and Gabriela Maron, MD (St. Jude Children's ResearchHospital). As coauthors of the ASTCT Practice Guidelines, "American Society for Transplantation and Cellular Therapy Best Practice Considerations for the Prevention and Management of Infections After Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies," recently published in Transplantation and Cellular Therapy, they discuss the implementation of critical strategies for safeguarding CAR T recipients.The conversation explores the nuances of the manuscript,providing a practical perspective on translating these consensus recommendations into clinical operations.Assessing the Burden of Immunosuppression: Evaluating the cumulative risk factors that predispose CAR T recipients to infection, including heavy pretreatment and the effects of lymphodepletion.Prophylaxis Optimization: Critical considerations regarding the timing, selection, and duration of antimicrobial regimens in the post-CAR T setting.Managing Hypogammaglobulinemia: A pragmatic look at IVIG replacement strategies, balancing emerging clinical evidence with institutional protocols and global product shortages.Addressing Evidence Gaps: Insider insights into the expert panel's deliberations on "grey areas," such as the management of CMV reactivation and optimal post-therapy vaccination schedules.The Pediatric-Adult Continuum: Ensuring that prevention and management strategies are robust and applicable across the full age spectrum of CAR-T recipients.This episode provides essential context for cliniciansseeking to move beyond the published guidelines and operationalize these bestpractices with greater precision and confidence.Thank you to Johnson & Johnson and Legend Biotech forsupporting this episode.

In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting.The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD negativity, treatment de-escalation, and prolonged drug holidays. Listen below or via your favorite podcast platform.

Das neue Jahr startet mit einer prall gefüllten Wundertüte: Dr. Anne Fleck beantwortet eure Zuschriften – unter anderem dazu, was gegen starke Neurodermitis helfen kann, wo Knackpunkte bei Migräne-Schmerzen liegen und was nach einem gravierenden Eingriff wie einer Herztransplantation beachten werden sollte. +++

AJT January 2026 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Al-Faraaz Kassam to discuss the key articles of the January issue of the American Journal of Transplantation. Al-Faraaz Kassam is an Assistant Professor in Transplant Surgery at Johns Hopkins University [03:45] Evaluation of kidney procurement biopsy and machine perfusion on allograft outcomes: A retrospective cohort study of the OPTN database [11:23] Improving the  histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants [23:01] Exosome-primed T cell immunity is facilitated by complement activation [32:26] Landscape of subclinical rejection in a large international cohort of pediatric kidney transplant (kTx) recipients [42:19] Donor Heart Preservation at 10°C After Thoracoabdominal Normothermic Regional Perfusion Lowers Rates of Severe Primary Graft Dysfunction and Improves Recipient Transplant Outcomes  

Send us a textHair transplantation ~ Succeeding as a female in a Male-Dominated FieldMargaret Zakhary is a surgical PA, licensed in 9 US states. She has a family history of hair loss, with her Mum first experiencing hair loss at 16 years old, when she suffered permanent scarring from chemical damage. She tried wearing a wig for hair loss, but it looked terrible!Later on, when she was only 33, she became very ill, and Margaret, being just ten, began experiencing hair loss herself, and since has had several forms of hair loss throughout her life.She believes in turning tragedy into purpose, and shares how these events inspired her to study hair loss, to ensure that every patient has an advocate, and that they can get the care they need.Connect with Margaret:Instagram Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the  data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes. Adams and Banerjee discussed abstracts from the meeting, including the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma who progressed on at least 1 prior line of therapy.1 A significant progression-free survival benefit was observed with the experimental combination compared with standard of care in this population. They also discussed data from cohort A of the phase 2 IFM2021-01 trial (NCT05572229), which evaluated subcutaneous teclistamab in combination with subcutaneous daratumumab in patients with newly diagnosed multiple myeloma. Results demonstrated that the combination was effective and safe in the frontline treatment of patients who were ineligible for transplant.2 The discussion also covered the broader treatment landscape, as the experts compared the use of bispecific antibodies with BCMA-directed CAR T-cell therapies. Frontline bispecific strategies for transplant-ineligible populations were also topics of conversation, as well as post-transplant consolidation with bispecifics. Ultimately, they stated that multiple myeloma care is undergoing a paradigm shift toward deeper minimal residual disease negativity, possible treatment de‑escalation, and even serious use of the word “cure” for the disease. Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center, and Adams is a clinical pharmacist in the Department of Stem Cell Transplant and Cellular Therapy and coordinator of the PGY-2 Oncology Residency at Orlando Health. Both are also members of the ASTCT content committee. References Mateos M-V, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6 Manier S, Lambert J, Marco M, et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort A. Blood. 2025;146(suppl 1):367. doi:10.1182/blood-2025-367

Olivier Soubrane est un très grand chirurgien qui a pris le temps de venir nous parler de sa vie et dont la pudeur et l'humilité nous obligent. Passionné par son métier, Olivier Soubrane consacre sa vie à sauver les nôtres. Très impressionnée par cet homme, j'en ai oublié ma retenue légendaire (!!) et allez comprendre pourquoi, j'ai raconté ma vie... j'espère que vous ne m'en voudrez pas. Mais l'essentiel est ailleurs. Alors le gout de la médecine et cette envie de faire de la chirurgie, la différence entre les médecins d'hier et ceux d'aujourd'hui, mais aussi ce qui le rend le plus heureux et le plus fier ou encore sa relation aux patients, la réaction hospitalière lors du COVID et ses plus grands souvenirs de chirurgie, tout cela et bien plus encore c'est à découvrir dans cet épisode. Le dernier de l'année donc...Merci de votre fidélité et de votre soutien. A bientôtJuliaGénérique composé par Jean ThéveninHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

A heartfelt memoir about the search for religion and identity “I'm not Jewish.” For years, that's what David Weill told anyone who asked about his religious background. Yes, his father was a Jew who had left Nazi Germany as a boy. But his mother was a Southern Baptist. Growing up in New Orleans, religion wasn't something his family discussed, let alone practiced. As an adult, he developed a fervent zeal and profound devotion to his work as a specialist in organ transplants. Transplantation was all he needed to define and fulfill him—until a crisis shook him to the core. In 2015, after the simultaneous unraveling of his carefully crafted career and the death of his father, Weill began to doubt everything, including his purpose in life. While grappling with emotional pain and sinking deeper into despair, he began to suffer perplexing physical symptoms. In his moment of crisis, he was seized by a strong desire to practice a formal religion. But for Weill, the real question was, Which religion? Eventually, he chose Catholicism and was baptized at age fifty. He found solace in heart-to-heart talks with a priest and his daughters' happiness at having the whole family at church together. Everything was fine—until 2020, when he learned that his mother had converted to Judaism right before marrying his father. He was born a Jew. And in the eyes of the Jewish faith, he would always be Jewish. That realization sparked his second quest. Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-like-it-s-live--4113802/support.

This week we go back in time 2 years to review a recent paper from 2023 about outcomes of cardiac transplantation in the adult congenital heart patient (ACHD). Little has been written on this topic until this very robust and large scale report. How do single ventricle ACHD patients fair at transplant and how do they compare to non-ACHD heart transplant recipients? Why might 1 and 3 year outcomes not be a 'fair' method of assessing outcomes in this very high risk patient group? How do HLHS patient outcomes compare with other single ventricles? Are there better ways to measure risk in this patient group and how might the data in this work inform risk stratification and management of failing Fontan patients in whom transplantation is being considered? These are amongst the questions posed this week to the week's expert, Dr Daphne Hsu who is Professor of Pediatrics at the Albert Einstein College of Medicine at The Children's Hospital at Montefiore.https://doi.org/10.1016/j.jacc.2023.06.037For those interested in learning more about Dr. Hsu, take a listen to episode #166 from June, 2021:https://www.spreaker.com/episode/pediheart-podcast-166-a-conversation-with-professor-daphne-hsu--45144274

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, Dr. Corey Cutler, from Dana-Farber Cancer Institute, and Dr. Guang-Shing Cheng, from the University of Washington and Fred Hutchinson Cancer Center, discuss how to identify and manage non-infectious lung complications following allogeneic transplant. From differentiating infection versus inflammation to managing conditions like organizing pneumonia (OP), this conversation offers practical insights for clinicians.For a deeper dive, explore Dr. Cheng's many publications on pulmonary topics in the Journal of Transplantation and Cellular Therapy. Additionally, read the article “Late-Onset Noninfectious Pulmonary Complications after Hematopoietic Stem Cell Transplantation” by Harris et al. shared in a September 2024 GVHD Supplement collection by the journal.

In this episode of ASTCT Talks, supported by an educational grant from Sanofi US, host Dr. Corey Cutler, MD, from Dana-Farber Cancer Institute, sits down with Dr. Sanjeet Singh Dadwal, MD, chief of infectious diseases at City of Hope, to explore a critical aspect of chronic graft-versus-host disease (GVHD): immune dysfunction and infection risk.The discussion highlights:• How chronic GVHD independently contributes to immune deficits and infection susceptibility.• Infectious risks associated with FDA-approved therapies for chronic GVHD.• Common infections in this population and why vigilance matters.• Practical guidance on prophylaxis strategies, vaccination timing, and navigating real-world challenges like food safety.This episode offers actionable insights for clinicians managing infection prevention and survivorship care in patients with chronic GVHD.Read “Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors,” included in the 2024 GVHD Supplement collection published by Transplantation and Cellular Therapy.

AJT December 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Hannah Bahakel to discuss the key articles of the December issue of the American Journal of Transplantation. Hannah Bahakel is a Clinical Immunodeficiency fellow at Cincinnati Children's Hospital Medical Center [03:34] Higher vs standard mean arterial pressure target in the immediate postoperative period of liver transplantation to prevent acute kidney injury: A randomized clinical trial (LIVER-PAM) [13:51] Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies [26:27] Tolerogenic lung allograft microenvironment suppresses pathogenic tissue remodeling following respiratory virus infection in mice [37:11] Therapeutic needs in solid organ transplant recipients: The American Society of Transplantation patient survey [48:19] Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Joseph Leventhal, Professor of Surgery and Director of Living Donor Kidney Transplantation at Northwestern University Feinberg School of Medicine. A pioneer in the field of organ transplantation, Dr. Leventhal's research is redefining what's possible in immune tolerance—an area often described as the “holy grail” of transplantation, where a patient's body can accept a donated organ without lifelong immunosuppressive drugs.Dr. Leventhal shares his journey from growing up in New York City to becoming one of the foremost leaders in transplant surgery and cell therapy innovation. He discusses how his team's groundbreaking clinical work has shown that tolerance can be achieved through cellular therapies, potentially freeing patients from the burdens of chronic immunosuppression.From the early days of cyclosporine to founding TRACT Therapeutics and developing first-in-human T-regulatory cell therapies, Joe reflects on the scientific curiosity, resilience, and collaboration that drive progress in a complex field. He also explores the evolving ecosystem for biotech innovation in Chicago, the challenges of translating academic research into clinical therapies, and the optimism surrounding the next generation of precision cell therapies.

In this episode, Prof. Fanny Mochel discusses the rationale and key findings from a retrospective cohort study of patients with CSF1R-related disorder treated with hematopoietic stem cell transplantation, highlighting the potential of this therapy to achieve both clinical and radiological disease stabilization. Journal CME is available until September 24, 2026 Read the article.

This week on Health Matters, Courtney talks with Dr. Robert Brown, the chief of gastroenterology and hepatology at NewYork-Presbyterian and Weill Cornell Medicine, to discuss the benefits and risks of taking dietary supplements, for our liver and our overall health. Dr. Brown offers tips for deciding which supplements to take, which to avoid, and ways we can optimize our liver health. ___Dr. Robert Brown is an expert in liver diseases, including alcohol-related liver disease, which affects up to 20 percent of the population, chronic hepatitis C infection, which affects an estimated 2.4 million Americans and cirrhosis, a scarring of the liver that is the third most common disease-related cause of death in the United States. He co-founded the Center for Liver Disease and Transplantation at NewYork-Presbyterian/Weill Cornell Medical Center, a joint program with Columbia University Irving Medical Center, in 1998. Dr. Brown will continue as medical director of this program, the largest for liver transplantation in New York City.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

CardioNerds kicks off its advanced therapies series with Chair of the CardioNerds Heart Failure Council, Dr. Jenna Skowronski, co-chair of the series, Dr. Shazli Khan, and Episode FIT lead, Dr. Jason Feinman. In this first episode, they discuss the process of advanced therapies evaluation with Dr. Michelle Kittleson, Professor of Medicine and Director of Education in Heart Failure and Transplantation at Cedars-Sinai. In this case-based discussion, they cover the signs and symptoms of end-stage heart failure, the initial management strategies, and the diagnostic workup required when considering advanced therapies. Importantly, they discuss the special considerations for pursuing left-ventricular assist device (LVAD) versus heart transplantation as well as the multidisciplinary, team-based approach needed when advanced therapies are indicated.  Notes were drafted by Dr. Shazli Khan.  Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Guideline-directed medical therapy (GDMT) is indicated in all heart failure patients and improves survival, but progressive symptoms and intolerance to GDMT can be warning signs of disease progression. The I-NEED-HELP mnemonic is an excellent reference when considering referral for advanced therapies (Figure).   Management of acute decompensation includes diuretics and possible inotropic support. The inotropic agent used should be whichever best suits your specific patient. Milrinone may result in more hypotension, whereas dobutamine may result in more tachycardia. Tachycardic and normotensive patients may do better with milrinone, while hypotensive patients with normal heart rates may do better with dobutamine. Notably, DoReMi found no difference between milrinone and dobutamine for patients with cardiogenic shock.  The initial diagnostic evaluation includes an echocardiogram, right heart catheterization (RHC), and often cardiopulmonary exercise testing (CPET) to objectively assess the status of the heart. Comprehensive labs, imaging and cancer screening are also needed to assess all other organs.   When making the decision to pursue advanced therapies, always ask:   Is the heart sick enough?   Is the rest of the body well enough?   These two questions provide a framework to guide if patients are optimal candidates for transplant versus LVAD.   The advanced therapies evaluation is a team sport! Patients will meet not only with advanced heart failure cardiologists, but also cardiac surgeons, psychiatrists, social workers, nutritionists and pharmacists. All team members are of critical value in the process.   Notes 1.) What are the key features of advanced cardiomyopathy, and when should providers consider referral for advanced therapies?   Advanced cardiomyopathy may present as recurrent hospitalizations for decompensated heart failure, intolerance to GDMT with symptomatic orthostasis and hypotension, and progressive symptoms of heart failure despite medical therapy.   The I-NEED-HELP mnemonic is a helpful tool to identify patients at risk of heart failure and is defined as follows: Need for Inotropic support, New York Heart Association (NYHA) Class IV symptoms, End-Organ Dysfunction, Ejection fraction

Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Christie Rampersad to discuss the key articles of the November issue of the American Journal of Transplantation. Christie Rampersad is clinical associate, in the Division of Nephrology at the University of Toronto in the Ajmera Transplant Centre [03:45] The early impacts of an attempt to standardize kidney procurement biopsy practices [13:40] The current state of simultaneous heart-liver transplantation in the United States [20:11] Engaging patients in organ transplant listing meetings: A survey study [37:32] Single-cell transcriptional landscape of liver transplant rejection reveals tissue persistence of clonally expanded, treatment-resistant T cells [45:32] Infectious disease surveillance and management in clinical xenotransplantation: Experience with the first human porcine kidney transplant

Professor Matteo Iannacone is Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory at Vita-Salute San Raffaele University. His work centers on understanding the generation of dysfunctional adaptive immune cells in chronic hepatitis B virus infection and developing new strategies to reprogram them into functional cells endowed with potent antiviral activity.

Cool air and warm soils mean that it's a great time to divide and multiply the plants that you love, and Leslie and Marianne want to help you do it easily, efficiently, and with the least amount of plant pain as possible. What are they dividing in their gardens and how are they doing it? And why is it so good for the plants to rip them from happy homes just when they were thinking of taking a well-earned nap? For that matter, why aren't the girls sipping pumpkin lattes and waiting ‘till spring? Set down that bulb planter and grab those two forks, because it's all about FREE this week on The Garden Mixer. (Just for the record Marianne hates pumpkin lattes. Leslie's a fan.)___________________Be sure to hit the subscribe button so we can keep you smiling while you hit the mess [your garden] out there.Full Show Notes at⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠The Garden Mixer Podcast's Substack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠____________________Socials – Pick Your Platform:Follow us on Instagram⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@thegardenmixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Indulge us on TikTok⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@the.garden.mixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spar with us on X⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@gardenmixerpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠“French Bistro” theme by Adieu Adieu. License D0LZBINY30GGTBBW

Première européenne: transplantation cardiaque partielle réussie chez un enfant Les brèves du jour Le bric à brac de Sapiens 5/5: un artiste nommé Sapiens "Vaccinez-moi" (2025) d'Alex Fredo pour parler des vaccins

It seems like every week, there's a new headline about some kind of sci-fi-esque organ transplant. Think eyeballs, 3D-printed kidneys, pig hearts.In her new book, Replaceable You: Adventures in Human Anatomy, science writer Mary Roach chronicles the effort to fabricate human body parts—and where that effort sometimes breaks down. Host Flora Lichtman speaks with Roach about everything from hair transplants to 3D-printed hearts, and why our anatomy is so hard to replicate in the first place.Guest: Mary Roach is a science writer and the author of Replaceable You: Adventures in Human Anatomy.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dans cet épisode, on lève le voile sur un sujet méconnu mais essentiel : le don de tissus humains. Caroline, coordonnatrice en prélèvement et développement, et Jimmy, spécialiste en tissus humains, nous expliquent comment ces dons peuvent transformer des vies, et pourquoi il est crucial d'en parler. Un échange éducatif, humain et sans filtre.  Nous vous rappelons que, si vous consentez au don de tissus, vous pouvez dès maintenant signer votre carte d'assurance maladie (RAMQ). L'autocollant à apposer sur la carte peut être commandé en ligne sur https://publications.msss.gouv.qc.ca/msss/document-000065/ ou encore, il vous sera remis lors du renouvellement de votre carte. Il est également essentiel d'en discuter avec vos proches afin de clarifier les volontés et décisions de chacun.  Le jeu de Carte Héma-Québec "La question qui tue pas" sera disponible, jusqu'à épuisement des stock, dans les Centres de dons Héma-Québec. 

Liver transplantation continues to evolve as strategies expand to address organ shortage and optimize outcomes. Normothermic machine perfusion (NMP) offers a novel way to preserve and assess donor livers prior to implantation. In this episode of Behind the Knife, our transplant team at University of Nebraska Medical Center discusses the latest evidence from randomized trials, practical applications in donation after circulatory death (DCD) grafts, and how NMP is shaping clinical decision-making in high-risk transplants.  Hosts -  Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan   - Jacqueline Dauch, MD, Assistant Professor, University of Nebraska Medical Center  -  Shaheed Merani, MD PhD, Associate Professor, University of Nebraska Medical Center  - Alan Langnas, DO, Professor, University of Nebraska Medical Center  Learning Objectives - Describe the principles of normothermic machine perfusion (NMP) and how it differs from static cold storage.  - Summarize the design and key outcomes of the PROTECT trial and the Chapman et al. trial on NMP in liver transplantation.  - Recognize the clinical scenarios where NMP provides the greatest benefit, particularly in high-risk grafts (e.g., DCD donors, high donor risk index).  - Apply a practical viability assessment framework for livers on NMP, including hemodynamics, bile production, lactate trajectory, and histology when indicated.  - Discuss the implications of NMP for allocation, system logistics, and future adoption trends in transplantation.  References   1.     Markmann JF, Abouljoud MS, Ghobrial RM, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial. JAMA Surg. 2022;157(3):189-198. doi:10.1001/jamasurg.2021.6781. https://pubmed.ncbi.nlm.nih.gov/34985503/ 2.     Chapman WC, Barbas AS, D'Alessandro AM, et al. Normothermic machine perfusion of donor livers for transplantation in the United States: a randomized controlled trial. Ann Surg. 2023;278(5):e912-e921. doi:10.1097/SLA.0000000000005934. https://pubmed.ncbi.nlm.nih.gov/37389552/ 3.     Nasralla D, Coussios CC, Mergental H, et al; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56. doi:10.1038/s41586-018-0047-9. https://pubmed.ncbi.nlm.nih.gov/29670285/ 4.     Brubaker AL, Sellers MT, Abt PL, et al. US liver transplant outcomes after normothermic regional perfusion vs standard super rapid recovery. JAMA Surg. 2024;159(6):677-685. doi:10.1001/jamasurg.2024.0520. https://pubmed.ncbi.nlm.nih.gov/38568597/ 5.     Wall A, Snoddy M, Du J, et al. The current landscape of in situ and ex situ machine perfusion utilization for liver grafts from cardiac donation after circulatory death donors in the US. Am J Transplant. 2025;25(3):574-582. doi:10.1016/j.ajt.2024.09.012. https://pubmed.ncbi.nlm.nih.gov/39293517/ 6.     Watson CJE, Gaurav R, Fear C, Swift L, Selves L, Ceresa CDL, Upponi SS, Brais R, Allison M, Macdonald-Wallis C, Taylor R, Butler AJ. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation. 2022 Dec 1;106(12):2391-2398. doi: 10.1097/TP.0000000000004263. https://pubmed.ncbi.nlm.nih.gov/36044364/ 7.     Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, Crick K, Wigmore SJ, Fear C, Cornateanu S, Randle LV, Terrace JD, Upponi S, Taylor R, Allen E, Butler AJ, Oniscu GC. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant. 2019 Jun;19(6):1745-1758. doi: 10.1111/ajt.15241. https://pubmed.ncbi.nlm.nih.gov/30589499/ 8.     Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. doi:10.1002/lt.22091.https://pubmed.ncbi.nlm.nih.gov/20677285/  9.     Kwong AJ, Kim WR, Lake JR, Schladt DP, Handarova D, Howell J, Schumacher B, Weiss S, Snyder JJ, Israni AK. OPTN/SRTR 2023 Annual Data Report: Liver. Am J Transplant. 2025 Feb;25(2S1):S193-S287. doi: 10.1016/j.ajt.2025.01.022. https://pubmed.ncbi.nlm.nih.gov/39947804/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Return to Sport After Meniscal Allograft Transplantation in Collegiate and Professional Athletes Sachs JP, Mufti YN, Rubin J, et al. Am J Sports Med. 2025 Sep 3. doi:10.1177/03635465251366445 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest VALD MoveHealth - https://movehealth.me/ Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux  

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

AJT October 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Christina Haugen to discuss the key articles of the October issue of the American Journal of Transplantation. Dr. Christina Haugen is an Assistant Professor of Surgery at the University of Cincinnati. [03:28] Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes—An analysis of COMPARE trial data [10:26] Donor-specific mesenchymal stem cell infusion in human and nonhuman primate kidney transplantation [19:21] Potential targeting of urokinase-type plasminogen activator receptor–formyl peptide receptor signaling to prevent recurrence in posttransplant primary podocytopathies [30:20] The relationship between cessation of brain and systemic circulation after withdrawal of life-sustaining measures [36:03] Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

In this week's replay episode from 3 years ago, we delve into the world of pediatric heart transplantation and the impact that race or insurance status may have on outcomes. What are the factors that explain worse outcomes for black children waiting for a heart transplant? How is the PHTS Racial Disparity Taskforce working to reduce inequities in this field? What role does insurance status have on these outcomes? We speak with noted heart failure and transplantation expert, Dr. Neha Bansal who is Associate Professor of Pediatrics at The Icahn School of Medicine at Mount Sinai about this recent PHTS multicenter study.DOI: 10.1016/j.healun.2022.12.002